Navigation Links
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
Date:5/24/2011

CAMBRIDGE, Mass. and ST. PAUL, Minn., May 24, 2011 /PRNewswire/ -- Radius Health, Inc. ("Radius") and 3M Drug Delivery Systems ("3M") today announced an agreement to collaborate on the development of a transdermal delivery option of BA058, Radius' novel, proprietary PTHrP (parathyroid hormone-related protein) analog, for the treatment of osteoporosis.

The BA058 Microneedle Patch will use 3M's patented Microstructured Transdermal System microneedle technology to administer BA058 through the skin, as an alternative to subcutaneous injection. The BA058 patch is expected to combine the ease, convenience, and self-administration attributes of a transdermal patch with the speed and efficiency of a traditional injection. Terms of the agreement were not disclosed.

"Poor adherence to prescribed osteoporosis therapy is a common and serious problem. Patients who drop their treatment unknowingly place themselves at high risk of fracture, which exacts an enormous toll in terms of human and economic cost," said C. Richard Lyttle, PhD, President and Chief Executive Officer of Radius. "By providing a more convenient treatment alternative to injection that can promote improved compliance, the BA058 Microneedle Patch will be well-positioned to drive expansion of the osteoporosis market."

Radius' BA058 Microneedle Patch product is currently undergoing Phase 1 clinical studies. The company's recently concluded Phase 2 human testing of an injectable form of BA058 showed that BA058 significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common osteoporotic fracture site located in the hip joint) after six months of therapy, with greater BMD gains relative to Forteo®, the reference drug used in the study.

"We are pleased to partner with Radius, a company with deep domain expertise in osteoporosis," said Jim Vaughan, Division Vice President and General Manager of 3M Drug Delivery Systems Division. "This collaboration continues the validation of 3M's microneedle patch technology and provides an excellent example of how our technology adds value for promising new therapeutic agents. We look forward to merging 3M's innovative microneedle technology with Radius' promising bone-building agent to bring this important new therapy to market."

About 3M Drug Delivery Systems (WWW.3M.COM/DDS)

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M's inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development, and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology.

About 3M

3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovative company that never stops inventing. With $27 billion in sales, 3M employs about 80,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3m.com or follow @3MNews on Twitter.

About Radius (WWW.RADIUSPHARM.COM)

Radius is a leading company developing a new generation of drug therapies for osteoporosis and women's health. BA058, Radius' novel, proprietary analog of PTHrP (parathyroid hormone-related protein), is in clinical development as a treatment for osteoporosis in two delivery options: BA058 Injection is a subcutaneous injection in Phase 3 clinical study; and the BA058 Microneedle Patch, currently in Phase 1 study, is a short wear-time, transdermal patch based on a microneedle technology from 3M Drug Delivery Systems that is intended to promote improved patient compliance and drive an expansion of the osteoporosis market. The company has a pipeline of additional drug candidate programs in earlier stages of development. Radius is located in Cambridge, Massachusetts.

Radius Contact:
Nick Harvey
(617) 551-4704

3M Contact:
Mary Kokkinen
(651) 733-8806


'/>"/>
SOURCE Radius
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
2. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
3. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System
5. Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
6. New Biopharmaceutical Company to Accelerate Delivery of Vaccines and Protein Therapeutics
7. PharMEDium Services, LLC Receives U.S. Patent 7,918,830 Entitled Safety Device for Drug Delivery Devices and Containers
8. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
9. Ikaria® Launches Next-Generation Drug-Delivery System
10. Brainlab and SurgiVision Announce Strategic Alliance in MRI-Guided Drug Delivery and Other Interventional MRI Technologies in Neurosurgery
11. Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):